Generic Complera Availability
Last updated on Apr 10, 2024.
Complera is a brand name of emtricitabine/rilpivirine/tenofovir, approved by the FDA in the following formulation(s):
COMPLERA (emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate - tablet;oral)
-
Manufacturer: GILEAD SCIENCES INC
Approval date: August 10, 2011
Strength(s): 200MG;EQ 25MG BASE;300MG [RLD]
Has a generic version of Complera been approved?
No. There is currently no therapeutically equivalent version of Complera available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Complera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate
Patent 10,857,102
Issued: December 8, 2020
Inventor(s): Oliyai Reza & Wiser Lauren & Menning MarkThe invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.
Patent expiration dates:
- January 14, 2033✓
- January 14, 2033
-
Patent 7,125,879
Patent expiration dates:
- April 21, 2025✓✓✓
- April 21, 2025
-
Compositions and methods for combination antiviral therapy
Patent 8,592,397
Issued: November 26, 2013
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
-
Compositions and methods for combination antiviral therapy
Patent 8,716,264
Issued: May 6, 2014
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
-
Combinations of a pyrimidine containing NNRTI with RT inhibitors
Patent 8,841,310
Issued: September 23, 2014
Inventor(s): Stoffels Paul
Assignee(s): Janssen R & D IrelandThe present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Patent expiration dates:
- December 9, 2025✓✓
- December 9, 2025
-
Compositions and methods for combination antiviral therapy
Patent 9,457,036
Issued: October 4, 2016
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
-
Compositions and methods for combination antiviral therapy
Patent 9,744,181
Issued: August 29, 2017
Inventor(s): Dahl Terrence C. & Menning Mark M. & Oliyai Reza
Assignee(s): Gilead Sciences, Inc.The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Patent expiration dates:
- January 13, 2024✓✓
- January 13, 2024
More about Complera (emtricitabine / rilpivirine / tenofovir)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (60)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antiviral combinations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.